IndraLab

Statements

UCHL1 inhibits cisplatin. 5 / 5
| 5
reach
"Furthermore, UCHL1 expression level is negatively related to cisplatin resistance in ovarian cancer and knockdown of UCHL1 increased cisplatin resistance."
24155778
reach
"Platinum-based chemotherapy is the standard of care for SCLC and NEPC patients.14 63 Specifically, cisplatin is one of the most commonly used platinum-based therapies for NEPC, SCLC, and poorly differentiated neuroblastoma.14 63 To test whether UCHL1 inhibition enhances the efficacy of cisplatin, we tested the synergistic interactions between cisplatin and the UCHL1 inhibitors LDN-57444 and IMP-1710 in neuroendocrine carcinoma cell lines in vitro."
38244540
reach
"Likewise, genetic loss of UCHL1 increased the therapeutic effect of cisplatin in NEPC (Figure S8F)."
38244540
reach
"Moreover, we have extended this finding to further experimentation and showed that knockdown of UCHL1 increased cisplatin resistance in both A2780 and IGROV1 ovarian cancer cells."
24155778
reach
"For example, the level of UCHL1 is negatively related to cisplatin resistance in ovarian cancer, and knockdown of UCHL1 promotes cisplatin resistance."
33718207